Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 8 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In light of the weaker yen, rising raw material prices and logistics costs, intensifying market competition, shipment delays caused by concerns over raw material supplies, slowing demand for medical products, and appreciation of local currencies at the Malaysian and Chinese subsidiaries.
| Item | Details |
|---|---|
| Net Sales | ¥10,000 million → ¥9,700 million（-3.0%） |
| Operating profit | ¥300 million → ¥200 million（-33.3%） |
| Ordinary income | ¥350 million → ¥250 million（-28.6%） |
| Profit attributable to owners of the parent | ¥250 million → ¥180 million（-28.0%） |
| Net income per share | 37.41 yen → 27.75 yen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 8 May 2026 |
| Previous-period results | Net sales: ¥9,777 million; operating profit: ¥211 million; ordinary profit: ¥297 million; net income attributable to owners of the parent: ¥232 million; earnings per share: ¥34.82 (fiscal year ended March 2026) |
| Reason for the revision | In light of the weaker yen, rising raw material prices and logistics costs, intensifying market competition, shipment delays caused by concerns over raw material supplies, slowing demand for medical products, and appreciation of local currencies at the Malaysian and Chinese subsidiaries. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the weaker yen, rising raw material prices and logistics costs, intensifying market competition, shipment delays for some logistics equipment caused by concerns over raw material supplies, slowing demand for medical products, and appreciation of local currencies at the Malaysian and Chinese subsidiaries weighed on performance.